Republican Senators Demand Accountability from FDA
A group of Republican senators is urging FDA Commissioner Marty McCulley to address concerns regarding misconduct at the agency, particularly following the approval of a new generic chemical abortion drug. The approval has drawn sharp criticism from many Republican lawmakers.
Bill Cassidy, a Republican senator from Louisiana and Chairman of the Senate Health, Education, Labor and Pensions (HELP) Committee, along with 16 other Republican senators, sent a letter to McCulley seeking clarity about the FDA’s recent endorsement of what they deem “dangerous” abortion pills. This generic medication was introduced by pharmaceutical company Evita Solutions on September 30 and has faced significant backlash from various lawmakers.
Other senators who supported the letter include Tommy Tuberville, Rand Paul, Josh Hawley, Pete Ricketts, Mike Lee, James Risch, John Cornyn, James Lankford, Lindsey Graham, Ted Budd, Marsha Blackburn, Roger Wicker, Jon Husted, Steve Daines, Tim Scott, and Mike Rounds.
The senators asserted in their communication, “To be clear, this authorization does not reduce the risks to identified women and does not protect them from forced drug use. It even goes against President Trump’s strong stance of being ‘the most pro-life president in history’ committed to safeguarding unborn children and ensuring women’s safety.”
They added, “Given that the FDA has approved another means of chemical abortion under the same flawed framework, it is crucial that we receive an update on our review of mifepristone and our plans for reinstating necessary safeguards.”
The Department of Health and Human Services, which oversees the FDA, has yet to respond to these inquiries.
Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, expressed her concerns, stating that abortion pills are “putting women’s lives at risk” in the U.S. She emphasized that these medications not only terminate pregnancies but also threaten women’s health, undermining pro-life laws at state levels.
Dannenfelser went on, “Despite the alarming reports we’re hearing daily, the FDA responded by permitting a more affordable version of a drug that ends a pregnancy and can lead to emergencies for women. We’re incredibly grateful for Chairman Cassidy and his colleagues for sending this oversight letter to the FDA.”
Moreover, a study released in April by the Ethics and Public Policy Center—a conservative think tank—found that about one in ten women experience serious adverse effects after taking abortion pills. Additionally, HHS Secretary Robert F. Kennedy Jr. confirmed that the FDA has initiated an investigation into the associated risks of mifepristone.
In an interview on October 2, Hawley shared his loss of confidence in FDA leadership following the approval of the generic version of this new abortion drug.
